Who was studied, and how
Three numbers in the abstract
Where each one falls
Only readable comparisons vote
Where it lands on the map
What it changes
Among 13 other studies
2,776people with cardiovascular disease, in this paper
The trial randomly assignedassigned by chance
rosuvastatin, 10 mg daily
placebo
Reported lower LDL cholesterol, no range given−43.0
No clear effect on combined primary end point−4%
No clear effect on deaths−4%
randomisedthe abstract, start to end
… lipoprotein (LDL) cholesterol levels was 43% in patients receiving …
… group vs. the placebo group, 0.96; 95% confidence interval [CI], …
… per 100 patient-years; hazard ratio, 0.96; 95% CI, 0.86 to 1.07; P=0.51).
← favours treatmentfavours comparator →
could be chanceNo interval given · direction only, strength unknown
Mean reduction in low-density lipoprotein (LDL) cholesterol levelsrosuvastatin, 10 mg daily vs placebo
−43.0
Combined primary end point (death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke)rosuvastatin, 10 mg daily vs placebo
HR 0.960.84–1.11
All-cause mortalityrosuvastatin, 10 mg daily vs placebo
HR 0.960.86–1.07
StatinsLipidsCardiovascular eventsAll-cause mortality
Statins × all-cause mortalityhelps?mixed
unlikelylikely
0.500.50 without it
Statins × cardiovascular eventshelps?replicated
unlikelylikely
0.860.86 without it
← favours treatmentfavours comparator →
1 / 7